Search Result

Results for "

hyperuricemic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (9) BCRP (1) Cadherin (1) Collagen (1) FXR (1) GLUT (3) Interleukin Related (1) Isotope-Labeled Compounds (3) NF-κB (1) NOD-like Receptor (NLR) (1) Reactive Oxygen Species (ROS) (2) Reference Standards (2) Reverse Transcriptase (1) SOD (1) TGF-β Receptor (1) Toll-like Receptor (TLR) (1) URAT1 (6) Xanthine Oxidase (6)
By Research Areas:	Cancer (9) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (14) Metabolic Disease (19)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0174

Olsalazine Disodium 2 Publications Verification	Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Olsalazine Disodium is an orally active prodrug of 5-ASA (HY-15027). Olsalazine Disodium can inhibit cells proliferation and induce apoptosis. Olsalazine Disodium can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine Disodium can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

HY-B0174A

Olsalazine 2 Publications Verification	Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

HY-N5116

Neoisoastilbin	Others	Metabolic Disease Inflammation/Immunology
Neoisoastilbin possesses antioxidant, anti-hyperuricemic and anti-Inflammatory activities .

HY-116694

Digallic acid	Apoptosis Reactive Oxygen Species (ROS) Reverse Transcriptase Xanthine Oxidase URAT1	Infection Metabolic Disease Inflammation/Immunology Cancer
Digallic acid is an antioxidant, antimutagenic, antigenotoxic, and anti-hyperuricemic compound. Digallic acid is a reverse transcriptase and XOD, URAT1 (IC₅₀: 5.34 μM) inhibitor. Digallic acid scavenges DPPH· and O2·− radicals. Digallic acid induces apoptosis. Digallic acid can be isolated from the fruits of Pistascia lentiscus .

HY-178342

Xanthine oxidase-IN-18	Xanthine Oxidase Reactive Oxygen Species (ROS) SOD	Metabolic Disease Inflammation/Immunology Cancer
Xanthine oxidase-IN-18 is a potent orally activeXanthine oxidase (XO) inhibitor (IC₅₀ = 0.263 μM). Xanthine oxidase-IN-18 exerts inhibition by directly and stably binding to the xanthine oxidase Mo-co active site. Xanthine oxidase-IN-18 exhibits reactive oxygen species (ROS) scavenging activity. Xanthine oxidase-IN-18 shows anti-hyperuricemia effects in a Potassium oxonate (HY-17511)-induced hyperuricemic rat model. Xanthine oxidase-IN-18 can be used for hyperuricemia, breast and lung cancer research .

HY-B0174AR

Olsalazine (Standard)	Reference Standards Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Olsalazine (Standard) is an orally active prodrug of 5-ASA (HY-15027). Olsalazine (Standard) can inhibit cells proliferation and induce apoptosis. Olsalazine (Standard) can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine (Standard) can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

HY-B0174R

Olsalazine Disodium (Standard)	Reference Standards Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Olsalazine Disodium (Standard) is an orally active prodrug of 5-ASA (HY-15027). Olsalazine Disodium (Standard) can inhibit cells proliferation and induce apoptosis. Olsalazine Disodium (Standard) can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine Disodium (Standard) can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

HY-106300

AA 193	Others	Cardiovascular Disease
AA 193 is a uricosuric agent. AA 193 increases urate excretion in hyperuricemic rats .

HY-168740

URAT1 inhibitor 11	URAT1	Metabolic Disease
URAT1 inhibitor 11 (Compound 7) is a URAT1 inhibitor with an IC₅₀ value of 0.18 μM. URAT1 inhibitor 11 exhibits potent hypouricemic effects in hyperuricemic zebrafish induced by Potassium oxonate (HY-17511) and Xanthine sodium salt (HY-W017389) .

HY-144456

Xanthine oxidase-IN-5	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC₅₀ value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable agent-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model .

HY-B0174AS

Olsalazine-13C6	Isotope-Labeled Compounds Apoptosis	Others Metabolic Disease Inflammation/Immunology Cancer
Olsalazine- ¹³C₆ is the ¹³C labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

HY-B0174AS2

Olsalazine-d3,15N	Isotope-Labeled Compounds Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Olsalazine-d₃, ¹⁵N is ¹⁵N and deuterated labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

HY-153972

URAT1&XO inhibitor 2	URAT1 Xanthine Oxidase	Metabolic Disease Inflammation/Immunology
URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC₅₀ of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a K_i value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia .

HY-183543

URAT1/GLUT9-IN-2	URAT1 GLUT	Metabolic Disease Endocrinology
URAT1/GLUT9-IN-2 (Compound 42) is a selective, orally active URAT1/GLUT9 inhibitor, with an IC₅₀ of 2.81 μM against URAT1 and an IC₅₀ of 12.53 μM against GLUT9. URAT1/GLUT9-IN-2 reduces serum uric acid levels and protects renal function. URAT1/GLUT9-IN-2 can be used in research related to hyperuricemia and hyperuricemic nephropathy .

HY-182294

HYJ-2	URAT1	Metabolic Disease Inflammation/Immunology
HYJ-2 is a URAT1 inhibitor and urate-lowering agent. HYJ-2 inhibits URAT1-mediated urate transport and interacts with key residues within the URAT1 binding pocket. HYJ-2 reduces serum urate levels in hyperuricemic mice without inducing liver or kidney injury. HYJ-2 shows low cytotoxicity to hepatocytes and renal cells. HYJ-2 does not significantly induce hepatocyte apoptosis or mitochondrial dysfunction. HYJ-2 can be used in studies related to hyperuricemia and gout .

HY-183658

URAT1/GLUT9-IN-3	URAT1 GLUT	Metabolic Disease Inflammation/Immunology
URAT1/GLUT9-IN-3 is an orally active URAT1/GLUT9 dual inhibitor with IC₅₀ values of 4.01 and 1.60 μM. URAT1/GLUT9-IN-3 inhibits URAT1-mediated uric acid uptake and GLUT9-mediated uric acid transport, reducing renal urate reabsorption. URAT1/GLUT9-IN-3 reduces serum uric acid levels in hyperuricemic mice. URAT1/GLUT9-IN-3 can be used for the researches of gout and hyperuricemia .

HY-182000

Xanthine oxidase-IN-23	Xanthine Oxidase BCRP GLUT	Metabolic Disease
Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type Xanthine oxidase inhibitor with an IC₅₀ of 3.33 μM. Xanthine oxidase-IN-23 directly binds to XOD in a reversible mixed-type manner to inhibit its catalytic activity. Xanthine oxidase-IN-23 upregulates ABCG2 and downregulates GLUT9 to promote renal urate excretion. Xanthine oxidase-IN-23 reduces serum urate levels and improves renal function in hyperuricemic mice. Xanthine oxidase-IN-23 can be used in the research of hyperuricemia .

HY-B0174AS3

Olsalazine-d6	Isotope-Labeled Compounds Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Olsalazine-d₆ is the deuterium labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.

HY-N17914

Smilaxchinoside A	Xanthine Oxidase	Metabolic Disease
Smilaxchinoside A is an orally active steroidal glycoside found in the roots of S. riparia. Smilaxchinoside A reduces serum uric acid levels and shows potent uricosuric activity. Smilaxchinoside A inhibits XOD activity and downregulates renal mURAT1 expression. Smilaxchinoside A can be used for the research of hyperuricemia .

HY-N17383

Ligusticum cycloprolactam	Toll-like Receptor (TLR) NF-κB Collagen Interleukin Related Cadherin NOD-like Receptor (NLR) TGF-β Receptor FXR Apoptosis	Metabolic Disease Inflammation/Immunology
Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N5116

Neoisoastilbin	Flavonoids Liliaceae Classification of Application Fields Isoflavanones Phenols Polyphenols Smilacis Glabrae Rhizoma Plants Disease Research Fields Inflammation/Immunology Source Classification	Others
Neoisoastilbin possesses antioxidant, anti-hyperuricemic and anti-Inflammatory activities .

HY-116694

Digallic acid	Pistacia lentiscus var. Chia Phenols Polyphenols Plants Anacardiaceae Source Classification	Apoptosis Reactive Oxygen Species (ROS) Reverse Transcriptase Xanthine Oxidase URAT1
Digallic acid is an antioxidant, antimutagenic, antigenotoxic, and anti-hyperuricemic compound. Digallic acid is a reverse transcriptase and XOD, URAT1 (IC₅₀: 5.34 μM) inhibitor. Digallic acid scavenges DPPH· and O2·− radicals. Digallic acid induces apoptosis. Digallic acid can be isolated from the fruits of Pistascia lentiscus .

HY-N17914

Smilaxchinoside A	Structural Classification Smilacaceae Smilax riparia A. DC. Plants Steroids Source Classification	Xanthine Oxidase
Smilaxchinoside A is an orally active steroidal glycoside found in the roots of S. riparia. Smilaxchinoside A reduces serum uric acid levels and shows potent uricosuric activity. Smilaxchinoside A inhibits XOD activity and downregulates renal mURAT1 expression. Smilaxchinoside A can be used for the research of hyperuricemia .

HY-N17383

Ligusticum cycloprolactam	Structural Classification Natural Products Umbelliferae Plants Echinacea angustifolia DC. Source Classification	Toll-like Receptor (TLR) NF-κB Collagen Interleukin Related Cadherin NOD-like Receptor (NLR) TGF-β Receptor FXR Apoptosis
Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease .

Cat. No.	Product Name	Chemical Structure

HY-B0174AS

Olsalazine-13C6
Olsalazine- ¹³C₆ is the ¹³C labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

Olsalazine-13C6

Olsalazine- ¹³C₆ is the ¹³C labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

HY-B0174AS2

Olsalazine-d3,15N
Olsalazine-d₃, ¹⁵N is ¹⁵N and deuterated labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

Olsalazine-d3,15N

Olsalazine-d₃, ¹⁵N is ¹⁵N and deuterated labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

HY-B0174AS3

Olsalazine-d6
Olsalazine-d₆ is the deuterium labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.

Olsalazine-d6

Olsalazine-d₆ is the deuterium labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks